Gender-affirming hormone therapy is an unmet need and community priority for transgender women.
HPTN 091 is a study assessing the feasibility, acceptability, preliminary impact of a multi-component strategy that provides HIV prevention services, gender-affirming hormone therapy, and Peer Health Navigation to improve pre-exposure prophylaxis (PrEP) uptake and adherence. This study will be enrolling about 310 transgender women (TGW), ages 18 or older, not living with HIV.
Photo by Dwight C. Andrews/McGovern Medical School at UTHealth Office of Communications